AstraZeneca closes acquisition of cell therapy company Neogene Therapeutics
Pharma giant AstraZeneca has closed the previously announced acquisition of Neogene Therapeutics, a US-based clinical-stage biotechnology company.
Neogene Therapeutics is engaged in the discovery, development, and manufacturing of next-generation T-cell receptor therapies (TCR-Ts).
AstraZeneca announced the deal to acquire the cell therapy company in November 2022 and offered a consideration of up to $320 million.
Neogene Therapeutics will now work as a fully-owned subsidiary of the pharma giant, with operations in Amsterdam and California.
AstraZeneca closes acquisition of cell therapy company Neogene Therapeutics. Photo courtesy of D Wells/Wikimedia Commons.
Recently, AstraZeneca signed a deal to acquire CinCor Pharma, a US-based clinical-stage biopharmaceutical company, for a transaction value of about $1.8 billion.